dc.contributor.author | Ma, TM | |
dc.contributor.author | Sun, Y | |
dc.contributor.author | Malone, S | |
dc.contributor.author | Roach, M | |
dc.contributor.author | Dearnaley, D | |
dc.contributor.author | Pisansky, TM | |
dc.contributor.author | Feng, FY | |
dc.contributor.author | Sandler, HM | |
dc.contributor.author | Efstathiou, JA | |
dc.contributor.author | Syndikus, I | |
dc.contributor.author | Hall, EC | |
dc.contributor.author | Tree, AC | |
dc.contributor.author | Sydes, MR | |
dc.contributor.author | Cruickshank, C | |
dc.contributor.author | Roy, S | |
dc.contributor.author | Bolla, M | |
dc.contributor.author | Maingon, P | |
dc.contributor.author | De Reijke, T | |
dc.contributor.author | Nabid, A | |
dc.contributor.author | Carrier, N | |
dc.contributor.author | Souhami, L | |
dc.contributor.author | Zapatero, A | |
dc.contributor.author | Guerrero, A | |
dc.contributor.author | Alvarez, A | |
dc.contributor.author | Gonzalez San-Segundo, C | |
dc.contributor.author | Maldonado, X | |
dc.contributor.author | Romero, T | |
dc.contributor.author | Steinberg, ML | |
dc.contributor.author | Valle, LF | |
dc.contributor.author | Rettig, MB | |
dc.contributor.author | Nickols, NG | |
dc.contributor.author | Shoag, JE | |
dc.contributor.author | Reiter, RE | |
dc.contributor.author | Zaorsky, NG | |
dc.contributor.author | Jia, AY | |
dc.contributor.author | Garcia, JA | |
dc.contributor.author | Spratt, DE | |
dc.contributor.author | Kishan, AU | |
dc.contributor.author | Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators, | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2022-11-25T09:11:56Z | |
dc.date.available | 2022-11-25T09:11:56Z | |
dc.date.issued | 2023-02-01 | |
dc.identifier.citation | Journal of Clinical Oncology, 2022, pp. JCO2200970 - | |
dc.identifier.issn | 0732-183X | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5573 | |
dc.identifier.eissn | 1527-7755 | |
dc.identifier.eissn | 1527-7755 | |
dc.identifier.doi | 10.1200/JCO.22.00970 | |
dc.description.abstract | PURPOSE: The sequencing of androgen-deprivation therapy (ADT) with radiotherapy (RT) may affect outcomes for prostate cancer in an RT-field size-dependent manner. Herein, we investigate the impact of ADT sequencing for men receiving ADT with prostate-only RT (PORT) or whole-pelvis RT (WPRT). MATERIALS AND METHODS: Individual patient data from 12 randomized trials that included patients receiving neoadjuvant/concurrent or concurrent/adjuvant short-term ADT (4-6 months) with RT for localized disease were obtained from the Meta-Analysis of Randomized trials in Cancer of the Prostate consortium. Inverse probability of treatment weighting (IPTW) was performed with propensity scores derived from age, initial prostate-specific antigen, Gleason score, T stage, RT dose, and mid-trial enrollment year. Metastasis-free survival (primary end point) and overall survival (OS) were assessed by IPTW-adjusted Cox regression models, analyzed independently for men receiving PORT versus WPRT. IPTW-adjusted Fine and Gray competing risk models were built to evaluate distant metastasis (DM) and prostate cancer-specific mortality. RESULTS: Overall, 7,409 patients were included (6,325 neoadjuvant/concurrent and 1,084 concurrent/adjuvant) with a median follow-up of 10.2 years (interquartile range, 7.2-14.9 years). A significant interaction between ADT sequencing and RT field size was observed for all end points (P interaction < .02 for all) except OS. With PORT (n = 4,355), compared with neoadjuvant/concurrent ADT, concurrent/adjuvant ADT was associated with improved metastasis-free survival (10-year benefit 8.0%, hazard ratio [HR], 0.65; 95% CI, 0.54 to 0.79; P < .0001), DM (subdistribution HR, 0.52; 95% CI, 0.33 to 0.82; P = .0046), prostate cancer-specific mortality (subdistribution HR, 0.30; 95% CI, 0.16 to 0.54; P < .0001), and OS (HR, 0.69; 95% CI, 0.57 to 0.83; P = .0001). However, in patients receiving WPRT (n = 3,049), no significant difference in any end point was observed in regard to ADT sequencing except for worse DM (HR, 1.57; 95% CI, 1.20 to 2.05; P = .0009) with concurrent/adjuvant ADT. CONCLUSION: ADT sequencing exhibits a significant impact on clinical outcomes with a significant interaction with field size. Concurrent/adjuvant ADT should be the standard of care where short-term ADT is indicated in combination with PORT. | |
dc.format | Print-Electronic | |
dc.format.extent | JCO2200970 - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | LIPPINCOTT WILLIAMS & WILKINS | |
dc.relation.ispartof | Journal of Clinical Oncology | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium Investigators | |
dc.title | Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM): A Pooled Analysis of 12 Randomized Trials. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-07-12 | |
dc.date.updated | 2022-11-24T14:49:12Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1200/JCO.22.00970 | |
rioxxterms.licenseref.startdate | 2022-10-21 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36269935 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley) | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1200/jco.22.00970 | |
icr.researchteam | Clinic Acad RT Dearnaley | |
icr.researchteam | Clin Trials & Stats Unit | |
dc.contributor.icrauthor | Dearnaley, David | |
dc.contributor.icrauthor | Hall, Emma | |
dc.contributor.icrauthor | Cruickshank, Clare | |
icr.provenance | Deposited by Mrs Jessica Perry (impersonating Prof Emma Hall) on 2022-11-24. Deposit type is initial. No. of files: 1. Files: Sequencing of Androgen-Deprivation Therapy of Short Duration With Radiotherapy for Nonmetastatic Prostate Cancer (SANDSTORM); A Pooled Analysis of 12 Randomized Trials.pdf | |